Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Phenotypes in Heart Transplantation: Implications for Prognosis and Personalized Follow-up.

Transplantation·2026
Same author

Multiorgan failure and in-hospital mortality in urgent heart transplantation: the PRESAGIO study.

Revista espanola de cardiologia (English ed.)·2026
Same author

One-year multicenter prospective real-world study of vericiguat effectiveness and safety in Spain.

ESC heart failure·2026
Same author

Left atrial flow and thrombosis risk from 4D CT contrast dynamics by physics-informed neural network and indicator dilution theory.

bioRxiv : the preprint server for biology·2026
Same author

DIA-PINN: A physics-informed machine learning method to estimate global intrinsic diastolic chamber properties of the left ventricle from pressure-volume data.

American journal of physiology. Heart and circulatory physiology·2026
Same author

In silico assessment of arrhythmic risk following the implantation of engineered heart tissues in porcine hearts with varying infarct locations.

PLoS computational biology·2026
Same journal

Acute Rejection Mediated by Preformed Anti-HLA-C Antibody in a Kidney Transplant Patient: A Case Report.

Transplantation proceedings·2026
Same journal

Liver Transplantation for Metastatic Neuroendocrine Tumors: A Single-Center Experience in a Brazilian Referral Center.

Transplantation proceedings·2026
Same journal

Analysis of the Cost of Maintaining Effective Donors and Nondonors of Organs and Tissues in Intensive Care Units.

Transplantation proceedings·2026
Same journal

Adolescence and Pediatric Heart Transplantation: Impact of Non-Adherence on Mortality: A Single-Center Experience.

Transplantation proceedings·2026
Same journal

Impact of Family-Based Care on the Outcome of Brain Death and Humanization in the Process of Multiple Organ Donation: Case Report.

Transplantation proceedings·2026
Same journal

Karnofsky Performance Status Is Associated with Patient and Graft Survival After Liver Retransplantation.

Transplantation proceedings·2026
See all related articles

Related Experiment Video

Updated: Jun 21, 2026

A Modified Cuff Technique for Mouse Cervical Heterotopic Heart Transplantation Model
06:45

A Modified Cuff Technique for Mouse Cervical Heterotopic Heart Transplantation Model

Published on: February 7, 2022

PCSK9 Inhibitors in Heart Transplant Recipients.

María Jesús Valero1, Carlos Ortiz-Bautista1, Javier Gonzalez-Martín2

  • 1Department of Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Spain Cardiovascular Disease Research Network (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain; Faculty of Medicine, Universidad Complutense de Madrid, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañon, Madrid, Spain.

Transplantation Proceedings
|June 19, 2026
PubMed
Summary
This summary is machine-generated.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors significantly reduced LDL cholesterol in heart transplant recipients. These PCSK9 inhibitors showed no apparent safety concerns, supporting their use for lipid management post-transplant.

Related Experiment Videos

Last Updated: Jun 21, 2026

A Modified Cuff Technique for Mouse Cervical Heterotopic Heart Transplantation Model
06:45

A Modified Cuff Technique for Mouse Cervical Heterotopic Heart Transplantation Model

Published on: February 7, 2022

Area of Science:

  • Cardiology
  • Immunology
  • Pharmacology

Background:

  • Dyslipidemia is a common complication following heart transplantation (HT).
  • Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors offer a potential therapeutic option for managing dyslipidemia in HT recipients.

Purpose of the Study:

  • To evaluate the efficacy and safety of PCSK9 inhibitors in a national cohort of heart transplant recipients.
  • To assess the impact of PCSK9 inhibitors on lipid levels and key clinical outcomes such as antibody development, coronary allograft vasculopathy, and rejection.

Main Methods:

  • Retrospective multicenter study including HT recipients from 8 Spanish centers.
  • Primary analysis focused on changes in total and LDL cholesterol at 1 month post-treatment.
  • Secondary outcomes included the incidence of donor-specific HLA antibodies (DSA), coronary allograft vasculopathy (CAV), and rejection.

Main Results:

  • Thirty-six HT recipients received PCSK9 inhibitors.
  • Median LDL cholesterol significantly decreased by 71 mg/dL at 1 month (from 119.5 to 50 mg/dL).
  • No significant differences were observed in the prevalence of DSA, CAV, or rejection before and after PCSK9 inhibitor treatment.

Conclusions:

  • PCSK9 inhibitors demonstrated a marked reduction in LDL cholesterol in heart transplant recipients.
  • No significant safety concerns were identified with PCSK9 inhibitor use in this cohort.
  • PCSK9 inhibitors may be beneficial for patients with suboptimal lipid control post-heart transplantation, warranting further investigation into clinical outcomes.